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A new model of renal microvascular endothelial injury. Although the
importance of injury with consequent activation of endothelium is well-
recognized in diseases affecting the glomerular endothelial cell (GEN),
research on GEN injury in vivo has been hampered by the lack of adequate
animal models. Here we report the establishment and characterization of
a new GEN injury model in rats. This model was induced by selective renal
artery perfusion with anti-GEN IgG and resulted in the severe acute renal
failure with marked platelet deposition and development of a thrombotic
microangiopathy involving glomeruli. Peritubular capillary endothelial
cells were also damaged that was associated with severe tubular necrosis.
Although the glomerular changes were severe, half of the glomeruli
recovered by day 10, while interstitial changes remained throughout our
observation time course. Proliferation of GEN was observed during the
recovery phase. An increased expression of endothelial nitric oxide
synthase in GEN was also observed, and may be an adaptive mechanism
to counteract the thrombosis and ischemia. This model should be useful to
investigate the pathophysiology of renal microvascular diseases and the
mechanisms of GEN injury, activation and recovery in vivo.
Vascular endothelium fuctions as a permeability barrier, con-
tributes to the regulation of vasomotor tone, mediates the fluidity
of the blood via a number of mechanisms, and is integral to the
development of inflammatory foci, both through hemodynamic
vasodilator effects and by recruitment of leukocytes. The endo-
thelium may not be merely a target for injury but also is actively
involved in the localization and propagation of inflammation.
Furthermore, under certain conditions the endothelium may
promote a procoagulant state which is likely to be of major
importance in the pathogenesis of vascular injury in many disease
states. Glomerular endothelium, as well as other endothelium,
plays a critical role in the pathophysiology of various disorders
such as glomerulonephritis, vasculitis, allograft rejection, isch-
emia-reperfusion injury, and thrombotic angiopathies. Injury and
activation of glomerular endothelial cells (GEN) has been exten-
sively studied in vitro [1—8]. However, research on the GEN injury
in vivo has been hampered by the lack of adequate animal models.
Here we report establishment and characterization of a new rat
model of GEN injury.
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METHODS
Induction of the GEN injury model
The GEN injury model was induced by selective perfusion of
the right kidney through the superior mesenteric artery with the
purified IgG of anti-GEN antibody. The technique of selective
renal artery perfusion was desribed previously [9]. Kidneys were
perfused with 0.2 ml of saline, followed by 80 mg/kg body wt of
anti-GEN IgG or control goat IgG in phosphate-buffered saline
(PBS), pH 7.2. When a dose response was performed, various
doses of IgG was used instead of 80 mg/kDa body wt. Ischemia
time was less than six minutes. In separate experiments, as
referred to in the Results section, various doses of anti-GEN IgG
were perfused and the unperfused left kidney was removed prior
to closing the abdominal incision.
Immunization of goat with cultured rat GEN
Culture of rat GEN and its characterization has been described
elsewhere [10].
A goat was immunized with 1 X iO rat GEN in complete
Freund's adjuvant (Sigma Chemical Co., St. Louis, MO, USA)
and 0.9% saline subcutaneously at multiple sites. The goat was
boosted every month with 1 x i07 cells emulsified with incomplete
Freund's adjuvant and 0.9% saline. After the second boost the
goat was plasmapheresed 10 days following imunization and IgG
was purified from the goat plasma as described below.
Purification of goat IgG
Goat IgG for renal artery perfusion was purified utilizing a
caprylic acid precipitation method as described before [11, 12].
Briefly, after adjusting the pH of the plasma to 5.5 with HC1, 5.5
ml/100 ml plasma of caprylic acid solution (Sigma) was added
dropwise with vigorous stirring. Then the solution was stirred for
one hour at room temperature and centrifuged at 14 K rpm for 30
minutes at room temperature. The supernatant was collected and
dialyzed against PBS. The dialyzed solution was centrifuged at 14
K rpm for 30 minutes at 4°C. This supernatant was sterilized by
filtration and stored at 4°C.
Experimental design
Fifty-two male Wistar rats weighing 200 to 300 grams were
used. All animal studies were performed in an accredited animal
care facility in accord with the NIH guidelines for the Care and
Use of Laboratory Animals.
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Renal biopsies were obtained 10 minutes, four hours, one day,
three days, and 10 days after the perfusion. At each time point at
least four anti-GEnC perfused animals and two control animals
were biopsied. Urine was collected from day 0 to day 1, day 1 to
day 2, and day 9 to day 10 for urine protein measurements. Serum
was obtained at day 1 and day 10 for serum BUN determination.
Platelet count and hematocrit was examined prior to and 24 hours
after the induction of the model.
Renal histology
Methyl Carnoy's fixed tissue was processed, and 4-jim sections
were stained with the periodic acid-Schiff reagent and counter-
stained with hematoxylin. The numbers of neutrophils, prolifer-
ating cells, and macrophages present per glomerular cross-section
were counted in a blinded fashion. Thirty randomly selected
glomeruli were examined per rat, and the average number of
positive cells per glomerulus was calculated. Glomerular cross-
sections containing only a minor portion of the glomerular tuft (<
20 discrete capillaiy segments per cross-section) were not utilized.
Tissue for immunofluorescence was embedded in 0. C. T.
(Lab-Tek Products; Miles Laboratories, Naperville, IL, USA) and
snap-frozen in isopentane.
Antibodies
Glomerular cell proliferation was assessed by staining with
19A2 (Coulter Corp., Hialiah, FL, USA), a mouse monoclonal
1gM antibody to the proliferative cell nuclear antigen. Glomerular
macrophages were stained with the monoclonal antibody ED-i
(Bioproducts for Science, Indianapolis, IN, USA) at the final
concentration of 0.4 tg/ml. GEN were stained with RECA-1, a
monoclonal IgG1 antibody specific for endothelial cells [13].
Glomerular platelet infiltration was assessed by staining with
PL-1, a murine monoclonal antibody to rat platelets (a gift from
W.W. Baker, University of Groningen, Groningen, the Nether-
lands) [141 at the final concentration of 5 j.g/ml. To stain
n-smooth muscle actin, asm-1 (Boehringer-Mannheim, Germa-
ny), a well characterized monoclonal antibody [15], was utilized at
the final concentration of 50 ng/ml. Collagen type IV was stained
with goat anti-collagen type IV antibody (Southern Biotech,
Birmingham, AL, USA) at the final concentration of 2.5 jig/mI.
Laminin was stained with rabbit anti-rat laminin antibody (Chemi-
con, Temecula, CA, USA) at the final concentration of 1.5 j.tglml.
Mesangial cells were stained with OX-7 anti-Thyl .1 monoclonal
IgG1 antibody (Serotec Ltd., Oxford, UK) at the final concentra-
tion of 0.4 /Lg!ml. Vascular endothelial growth factor (VEGF) was
stained with affinity purified rabbit anti-VEGF polyclorial anti-
body (Santa Cruz Biotech, Inc., Santa Cruz, CA, USA) [16] at the
final concentration of 1 jtglml. Endothelial nitric oxide synthease
(eNOS, NOS III) was stained with mouse anti-eNOS monoclonal
JgG1 antibody (Transduction Lab., Lexington, KY, USA) [17] at
the final concentration of 0.08 j.g/ml.
To detect proliferation of endothelial cells, double immuno-
staining was performed as described previously [18]. Briefly, tissue
was incubated with RECA-1 (a monoclonal IgG) and with
anti-PCNA (a monoclonal 1gM) followed by biotinylated rabbit
anti-mouse IgG1 (Zymed, San Francisco, CA, USA), avidin
D-peroxidase, and diaminobenzidine reaction without nickel chlo-
ride, and then peroxidase-conjugated rat anti-mouse 1gM
(Zymed) antibody, followed by diaminobenzidine containing
nickel chloride. Controls included either deletion of the primary
antibody or substitution of irrelevant monoclonal antibodies of
the same isotype. To detect proliferation of mesangial cells or
macrophages, OX-7 or ED-i was used instead of RECA-i.
Fibrinogen was detected by staining with FITC-conjugated goat
anti-fibrinogen IgG (Cappel, Durham, NC, USA) at the final
concentration of 25 pg/ml. Rat C3 was detected with FITC-
conjugated goat anti-rat C3 (Cappel).
Electron microscopy
Tissue for electron microscopy (EM) was fixed in half-strength
Karnovsky's solution (1% paraformaldehyde and 1.25% glutaral-
dehyde in 0.1 M Na cacodylate buffer, pH 7.0), postfixed in
osmium tetroxide, dehydrated in graded ethanols, and embedded
in epoxy resin. Thin sections were stained with uranyl acetate and
lead citrate and examined with a Philips 410 (Philips Export By,
Eindhoven, The Netherlands) electron microscope.
Serum BUN and urinary protein measurement
BUN was determined colorimetrically utilizing a commercial kit
for the measurement of urea nitrogen (Sigma Diagnostics, St.
Louis, MO, USA).
Urine protein excretion was measured using the sulfosalicylic
acid method [19].
Western blotting analysis
Western blotting was performed using the crude extracts of
cultured GEN and 10 tg/m1 of anti-GEN IgG. The bound
antibody was detected with alkaline phosphatase streptavidin
(Vector Lab., Burlingame, CA, USA) following incubation 0.75
jig/mi of biotinylated rabbit anti-goat IgG (Zymed). BCIP/NBT
tablets (Sigma) were used as a substrate.
Statistical analysis
Data are reported as mean SD. Data are analyzed by
Student's t-test with adujstments using the BonferronilDunn
method.
RESULTS
Acute renal failure was induced by anti-GEN perfusion
One day after induction of disease, serum BUN levels of
anti-GEN perfused rats were significantly higher (25.3 2.2
mg/dl, N = 5) than controls (18.7 1.9 mgldl, N = 4; P < 0.005).
BUN levels of anti-GEN perfused rats were still elevated at day 10
(28.0 4.4, N = 4). These rats also demonstrated a slight increase
in urinary protein excretion at day 0 to 1 (38.6 6.6 mg/day, N =
5) compared with control animals (21.0 3.5 mg/day, N = 4; P <
0.005). Proteinuria in the diseased rats decreased to 21.9 5.6
mg/day at dayl to 2 (P < 0.005). At day 10 the animals perfused
with anti-GEN IgG excreted 3.9 1.0 mg/day of protein (N = 4),
while the amounts of protein in urine of control rats were 6.5
1.0 (N = 2).
Although the increase in BUN levels described above was
statistically significant, the magnitude was small. We speculated
that this could be explained by compensation in the left kidney. To
confirm this hypothesis, we also perfused uninephrectomized rats
with anti-GEN or control IgG. BUN of the uninephrectomized
rats perfused with anti-GEN at day 1 was 174 24 mg/dl (N =2),
compared to 31.3 2.8 in controls (N = 2). Furthermore, the
increase in BUN in uninephrectomized rats was dependent on the
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Fig. 1. Increases of serum BUN levels were dependent on the amounts of
anti-GEN IgG in uninephrectomized rats. Rats perfused with 80 mg/kg
body wt of anti-GEN IgG demonstrated 173.7 23.9 mg!dl of BUN, while
BUN levels of the rats perfused with 26.7, 13.3, and 6.7 mg/lcg body wt of
anti-GEN were 75.5 10.1, 41.9 5.7, 27.0 0.8mg/dl, respectively (0).
Rats perfused with 80 mg/kg body wt of control goat IgG showed 31.3
2.8 mg/dl of BUN (A). N = 2 for each dose.
amounts of anti-GEN IgG administered (Fig. 1). We also mea-
sured proteinuria in the uninephrectomized rats perfused with
anti-GEN or control IgG at the same dose used for non-
nephrectomized rats. Proteinuria in the uninephrecomized rats
perfused with 80 mg/kg body wt of anti-GEN did not differ from
that of control rats (12.1 1.8 mg/day, and 10.5 0.5, respec-
tively).
Thrombocytopenia and anemia were induced by anti-GEN
perfusion
As thrombocytopenia and non-immune hemolytic anemia are
common denominators of thrombotic microangiopathy which is
also associated with renal microvascular injury, we examined if
these features occurred after the perfusion of anti-GEN IgG.
Platelet counts and hematocrits prior to the perfusion were not
significantly different between the rats perfused with anti-GEN
lgG (N = 4) and the animals perfused with control goat IgG (N =
4; Table 1). One day after perfusion, platelet counts of anti-GEN
perfused rats decreased to 71.3 18.1% of the original value,
while platelet numbers of control rats remained at 96.8+7.9%
(P < 0.05). Hematocrits of the anti-GEN perfused rats also
decreased to 77.8 5.0%, while those of the control animals were
91.9 1.7% one day after the perfusion (P < 0.005). The
decrease in hematocrit could be explained by hemolysis. Although
our anti-GEN lgG showed a weak cross reactivity with red blood
cells (data not shown), we think that hemolysis is mainly due to
intravascular mechanical fragmentation of red blood cells, which
was suggested by the presence of schistocytes and helmet cells on
the peripheral blood films at day 1 (Fig. 2).
Histology of the kidney
Histology of the kidney was examined by PAS staining. Ten
minutes after the perfusion, platelet aggregation was observed in
the capillary loops of the glomerulus. At day 1 capillary walls were
indistinct, and tubular damage was also apparent. Some tubules
were necrotic, and white blood cell casts were occasionally
observed within the tubular lumens (Fig. 3A). Varying degrees of
tubular necrosis was observed, which was often severe and patchy.
Arterioles frequently demonstrated denuded or swollen endothe-
hum, and the vasa rectae bundles in the outer medulla were
uniformly injured with loss of endothelium. Marked infiltration of
polymorphonuclear leukocytes was present in the interstitium
(Fig. 3B), while no significant infiltration of these cells was
observed in the glomerulus. At day 10, about one half of the
glomeruhi looked grossly normal, while the other half showed
some mesangial expansion. The vasa rectae and swollen arterioles
had recovered normal architecture. Larger vessles (interlobular
and arduate) showed an increase in cellularity in the adventitium.
Marked atrophy or dilation of the tubules and interstitial fibrosis
was also observed (Fig. 3C). None of these features were present
in control rats perfused with non-immune IgG.
Silver staining demonstrated that some of the glomeruli of
anti-GEN perfused rats were already sclerotic at day 10 (Fig. 3D).
Normal (control) goat IgG perfused rats had normal histology.
Electron microscopic analysis
Within 10 minutes of perfusion with the anti-GEN IgG, gb-
meruli demonstrated widespread aggregation of platelets within
capillary lumina. Many platelets could be seen adherent to the
capillary endothelium (Fig. 4). Circulating mononuclear leuko-
cytes were also present in capillary lumina. Capillary endothelium
generally maintained a normal appearance, and endothelial fen-
estrations remained preserved. No evidence of accumulation of
fibrin tactoids, immune complex formation, or injury to other
glomerular cell types was present. Changes in the tubules were
inapparent. Peritubular capillaries also demonstrated widespread
accumulation of platelets similar to that encountered in glomer-
ular capillaries.
At four hours, there was little change in the injury to glomerular
and peritubular capillaries. Accumulations of platelets were
widely persistent. Glomerular endothelium focally demonstrated
some degree of swelling and even focal denudation, but generally
remained preserved. Mesangial structure and epithelial cell foot
processes remained preserved. Immune complex formation and
accumulation of fibrin tactoids remained undetectable. The single
striking change from the 10 minute biopsies was widespread
necrosis of tubular epithelial cells, with extensive sloughing of
cells and cell cytoplasm into the tubular lumina.
At twenty-four hours, the accumulations of platelets persisted
in the glomerular capillary loops, but in some loops there were
now identifiable fibrin thrombi present as well. Red blood cell
fragments could be found within the platelet-fibrin mesh in some
capillary lumina. Glomerular endothelium was frequently swollen
and endothelial denudation from basement membranes more
widespread than was present at four hours. In some glomeruli,
there was clear evidence of mesangiolysis, with accumulations of
electron lucent material mixed with cellular debris present in
mesangial regions and extending into the subendothelial space of
adjacent capillary walls. Peritubular capillary endothelium showed
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Table 1. Platelet counts and hematocrits during the study period
Prior to disease Day 1
-
Decrease ratio
Platelet count of disease rats 896,000 62,600 plts/Lrl 640,000 17,900 plts/cd 71.3 18.1%
Platelet count of control rats 820,000 42,100plts/d 792,000 38,100plts/.d 96.8 7.9%
Hematocrit of disease rats 50.3 2.4% 39.0 1.4% 77.8 5.0%
Hematocrjt of control rats 49.5 1.3% 45.5 17% 91.9 1.7%
Abbreviation pits is platelets.
intensity did not change at four hours and at day 1. The staining
with anti-goat IgG decreased in intensity at day 3. The glomeruli
were still positive at day 10, although the fluorescence intensity
was faint.
The peritubular capillaries and arterioles irs the kidney were
also positive at 10 minutes, four hours, and day 1. The non-
glomerular renal microvascular staining decreased substantially
after four hours. Large vessels (interlobular) and venous endo-
thelium showed minimal staining at all time points.
In order to find out exactly what antigens this polyclonal
anti-GEN antibody is directed toward, Western blotting analysis
utilizing crude extracts of cultured GEN was performed. The blot
showed multiple bands (data not shown), and we could not
deduce what was the most prominent antigen for this antibody by
this analysis.
GEN injury
Fig. 2. Signs of erythrocyte fragmentation. Intravascular fragmentation
of red blood cells was suggested by the presence of schistocytes and helmet
cells on the peripheral blood film at day 1 in anti-GEN antibody perfused
rats (magnification X400).
prominent swelling and focal degenerative changes. Cortical
tubules demonstrated a range of appearances from morphologi-
cally normal to overt necrosis. At this time point, majority of
infiltrating leukocytes were in peritubular capillaries.
At day 3, all features of injury identified at day 1 were still
present, but the extent of glomerular capillary thromboses, and
the accumulations of subendothelial electron lucent material,
were more florid. Mesangiolysis persisted. Extensive tubular
necrosis remained evident. About one half of leukocytes were out
of the capillaries, while the other half were still in capillary
lumina.
By day 10, most of the mesangiolytic injury had resolved. The
accumulations of subendothelial electron lucent material were no
longer present, and the capillary loops were generally lined by
fenestrated, morphologically normal endothelium. In some capil-
lary ioops, occasional platelets and monocytes were still present.
Some mesangial regions remained modestly expanded due to
increased number of cells and some accumulated extracellular
material. Peritubular capillaries resumed a normal morphologic
appearance. Cortical tubules were largely reconstituted with
intact brush borders and complex basolateral interdigitations of
cell borders.
Anti-GEN IgG was localized along the glomerular capillaries
The glomeruli of the animals perfused with anti-GEN IgG
demonstrated bright linear staining in a capillary pattern with
anti-goat lgG antibody at 10 minutes (Fig. 5A). The staining
GEN morphology was assessed by staining with the endothelial
cell specific monoclonal antibody, RECA-1. The staining pattern
remained unchanged 10 minutes after the perfusion. At four
hours some glomeruli showed a decrease in RECA-1 staining,
although most glomeruli demonstrated a normal staining pattern.
At day 1 most glomeruli showed decreased RECA-1 staining to
some extent (Fig. 6 A, B), consistent with GEN injury. At day 3
approximately one half of the glomeruli recovered an intact
RECA-1 staining, while the rest still showed a decrease of the
staining. At day 10 all glomeruli demonstrated an intact RECA-1
staining pattern.
Platelet and neutrophil infiltration
Marked platelet aggregation within glomerular capillaries was
observed at 10 minutes after the perfusion (Fig. 6 C, D). Intense
staining with anti-platelet antibody persisted until day 1. At day 3
many glomeruli were free of anti-platelet staining, although there
were some glomeruli that still had prominent platelet aggregation
within them. At day 10 no anti-platelet staining was observed in
the glomeruli. Platelet infiltration was also observed in the
peritubular capillaries. Such infiltration was localized only in the
cortical area. Platelet aggregation in muscular arteries was much
less than that observed in microvessels.
In contrast to the marked platelet infiltration, there was no
significant neutrophil infiltration within glomeruli at any of the
time points investigated, although marked interstitial neutrophil
infiltration was observed at day 1 and day 3 in association with
leukocyte casts (Fig. 3).
Deposition of fibrin
Fibrin was already deposited in glomeruli 10 minutes after the
perfusion (Fig. SB). Four hours later deposition of fibrin had
increased, and at day 1 and day 3 most glomeruli showed
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Fig. 3. Histology of the kidney. (A) White blood cell casts were observed within the tubular lumens at day I (PAS staining). (B) Marked infiltration
of polymorphonuclear leukocytes was observed in the interstitium at day 1 (PAS staining). (C) Severe tubulointerstital damage, including tubular
dilatation and atropy, was observed at day 10 (Silver staining). (D) Some of the glomeruli demonstrated focal sclerosis at day 10 (Silver staining;
magnification x400).
prominent fibrin deposition. At day 10 no fibrinogen deposition
was observed in glomeruli.
Deposition of complement components in the glomerulus
Deposition of C3 was observed along the capillary walls at 10
minutes (Fig. SC). Intensity of C3 staining decreased four hours
after the perfusion, and no C3 deposition was observed 24 hours
after the perfusion. No staining of C3 was observed in control
glomeruli.
Macrophage infiltration
A significant infiltration of ED-i positive macrophages in
glomeruli was observed only at day 3 (4.0 1.0 ED-i positive
cells/glorneruli in the anti-GEN perfused rats, N = 4, vs. 1.3 0.1
in the control rats, N = 2, P < 0.001; Fig. 7).
Four hours after the induction of disease a few infiltrating
macrophages were observed in the interstitium. At day I intersti-
tial macrophage infiltration dramatically increased, and persisted
at day 3. At day 10 the interstitial macrophage infiltration was still
prominent.
Mesangial area
To examine if the mesangial cells were also involved in this
model, we investigated the distribution pattern of cells positive for
OX-7 (Thyl) staining, a marker of mesangial cells, and expression
of a-smooth muscle actin, a marker of mesangial cell activation.
At day 1 the mesangial areas appeared normal, and there were
no glomeruli that expressed a-smooth muscle actin. However, at
day 3 mild mesangial expansion was observed with OX-7 staining
(Fig. 8A), compared to control (Fig. 8B). Some glomeruli showed
a-smooth muscle actin expression at day 3 (Fig. 8C), although the
expression level was much lower than that observed in the
anti-Thyl mesangioproliferative glomerulonephritis model of rats
(data not shown). Distribution of mesangial cells returned to
normal and no a-smooth muscle actin expression was observed at
day 10. It should be noted that there were many a-smooth muscle
actin positive cells in the interstitium at day 3 and day 10 (Fig.
8D).
Glomerular cell proliferation was increased at day 3
Glomerular cell proliferation was assessed by PCNA staining.
At day 1 no significant increase in cell proliferation was observed.
A significant increase of PCNA positive cells in glomeruli was
observed only at day 3 (5.5 2.0 PCNA positive cells/glomeruli in
the anti-GEnC perfused rats, N = 4, vs. 0.2 0.1 in the control
rats, N = 2, P < 0.001). To determine which glomerular cells were
proliferating, we performed double staining with PCNA and
RECA-1, OX-7, or ED-i. No proliferation of macrophages was
detected in the glomerulus. Most of the PCNA positive cells were
endothelial cells (Fig. 9), but a small portion of these cells were
mesangial cells (OX-7 positive). We also observed proliferation of
peritubular capillary endothelial cells and tubular cells (Fig. 9).
No significant glomerular cell proliferation was demonstrated at
day 10.
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Fig. 4. Electron microscopic analysis. (A) 10 minutes after perfusion with the anti-GEN IgG, many platelets could be seen adherent to the capillary
endothelium. Capillary endothelium generally maintained a normal appearance, and endothelial fenestrations remained preserved. (B) One day after
perfusion, persistent accumulations of platelets were observed in the glomerular capillary loops. Intracapillary accumulations of finely fibrillar fibrin
tactoids were now apparent (arrow). Red blood cells and red blood cell fragments were also found within the platelet-fibrin mesh in some capillary
lumina. (C) One day after perfusion, glomerular endothelium was swollen and endothelia] denudation from basement membranes was widespread.
Mesangiolysis (M) was also observed in some glomeruli, with accumulations of electron lucent material mixed with cellular debris present in mesangial
regions and extending into the subendothelial space (S) of adjacent capillary walls. (D) At day 3, accumulation of electron lucent material in the
disrupted mesangial regions (M) was still apparent. There was now widespread extension of this material into the subendothelial space (S) of adjacent
capillary walls, similar to the glomerular injury characteristic of human thrombotic microangiopathy. (E) At day 10, most glomeruli recovered normal
morphologic features with normal endothelial appearances. A few residual platelets could be detected in some capillary lumina.
Fig. S. Glomerular deposition of anti-GEN IgG, fibrinogen, and C3 by immunofluorescence. (A) 10 minutes after the perfusion, anti-GEN IgG was
clearly demonstrated on the capillary walls in the glomerulus in a linear pattern. Deposition of anti-GEN lgG was also demonstrated in the periubular
capillaries (inset). (B) Marked deposition of fibrinogen was observed 10 minutes after the perfusion. (C) C3 deposition was observed on the capillary
walls 10 minutes after the perfusion (magnification X400).
VEGF expression in the glomerutus was increased at day 1 the same period, we speculated that some growth factors might be
As the glomerulus was recovering GEN staining (RECA-1) at inducing recovery by stimulating GEN proliferation. Therefore,
day 3 and the peak of cell proliferation (PCNA) was observed at we examined the expression of one of the well-known endothelial
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Fig. 6. Staining of GEN and platelets. (A) At
day 1 most glomeruli showed a decrease in
GEN staining as determined by RECA-1
staining. (B) Control rats showed intact RECA-
I staining along the glomerular capillary walls
at day 1 (C) Marked aggregation of platelets
was observed 10 minutes after the perfusion by
PL-1 staining. (D) No aggregation of platelets
was observed in control rats (magnification
x400).
Fig. 7. Macrophage infiltration. (A) Significant
macrophage infiltration was observed at day 3
by ED-i staining. It should be noted that
macrophage infiltration was also prominent in
the interstitium. (B) No significant increase of
macrophage infiltration was observed in control
rats (magnification x400).
cell growth factors, VEGF. We observed a marked increase of
VEGF production in the glomerulus at day 1, which appeared to
he primarily localized to the glomerular epithelial cells (Fig. 10 A,
B).
eNOS was up-regulated by GEN
Nitric oxide (NO) is a well-known mediator of various biolog-
ical phenomenon, including as a vasodilator and as an inhibitor of
platelet aggregation. Thus, we performed staining with anti-eNOS
antibody. We observed significant up-regulation of eNOS at four
hours and day 1 (Fig. 10 C, D). The staining pattern suggested
that eNOS was being expressed by the GEN.
Extracellular matrix protein
Marked deposition of type IV collagen in the glomerulus was
observed at day I and day 3 (Fig. 11). At day 10 type IV collagen
levels in one half of the glomeruli returned to normal. In contrast,
type IV collagen level in the interstitium dramatically increased at
day 10.
Laminin deposition in the glomerulus was also increased at day
1 and day 3 (Fig. 11). At day 10 laminin expression of one half of
the glomeruli returned to normal. In contrast, laminin deposition
in the interstitium increased at day 3 and persisted until day 10.
A summary of these immunohistochemical analyses described
above are shown in Table 2.
Other organs
We also examined liver, lung, spleen, and heart of anti-GEnC
perfused and control rats. These organs from the animals per-
fused with anti-GEnC IgG showed positive staining of microvas-
cular endothelium with anti-goat IgG compared with control rats,
although the staining was very faint. No tissue damage was
detected by H/E staining of these organs.
Nangaku et al: A new model of GEN injuly 189
Fig. 8. Mesangial changes. (A) OX-7 (Thyl)
staining showed mild mesangial expansion in
some glomeruli at day 3. (B) Control rats
showed a typical mesangial pattern of OX-7
staining. (C) In a small number of glomeruli, a
slight expression of a-smooth muscle actin was
observed at day 3. (D) Many a-smooth muscle
actin expressing cells were observed in the
interstitium at day 10 (magnification X400).
Fig. 9. Double staining with RECA-1 and PCNA. Indirect immunoperox-
idase double-immunostaining for PCNA (represented by the black nuclear
stain) and RECA-1, a marker for endothelial cells (represented by the
brown cytoplasmic stain), was performed. A representative glomerulus at
day 3 of anti-GEN perfused rats showed that most PCNA-positive cells
were GEN (examples are indicated by the broad arrows). Proliferation of
peritubular capillary endothelial cells was also observed (represented by
the thin arrow) (magnification X400).
DISCUSSION
We report a new model of GEN injuty. A major problem in
GEN injury research has been a lack of animal models. Among
the most important glomerular diseases in which GEN are a
principal target of injury is renal thrombotic microangiopathy
(TMA) such as hernolytic uremic syndrome (HUS). HUS shows
acute GEN injury that results in renal TMA with platelet con-
sumption and thrombocytopenia, fibrin deposition, non-immune
hemolytic anemia with fragmented erythrocytes, and renal failure
[20—23]. Most cases of epidemic HUS are associated with enteric
infection with verotoxin-containing E. coil 0157, in which it is
believed that the verotoxin mediates the disease [20, 24, 25].
Although a verotoxin-induced model of HUS might be ideal, the
Gb3 receptors required for binding of the toxin are not present on
rabbit GEN (as opposed to human GEN), and therefore injection
of verotoxin has not induced renal disease in rabbits [26]. To our
knowledge, nobody has succeeded in making HUS-like lesions in
rats by injection of verotoxin, either. Furtheriore, HUS also
occurs in the setting of other infections (such as Shigella, or
human immunodeficiency virus), drugs (mitomycin C, cyelospor-
me), severe hypertension, and pregnancy, or can be idiopathic.
Thus, the development of a model of GEN injury would be very
useful to elucidate the mechanisms of GEN injury, activation, and
recOvCry.
Several GEN injury models have been previously reported.
Matsuo et a! reported glonierulonephritis induced by anti-angio-
tensin converting enzyme antibody administration in rabbits [27].
However, due to the paucity of expression of the antigen within
the glomerulus, the disease was mild and transient. Matsuda
induced glomerular disease by immunizing guinea pigs with the
membrane products from cultured brain endothelial cells [28].
However, the disease was also mild and was accompanied by
neurological symptoms.
The two best models available so far utilized implanted antigen-
antibody reactions on the glomerular capillary walls. The first one
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Fig. 10. VTEGF and eNOS was up-regulated at
day 1. (A) Staining of VEGF was markedly
increased at day 1 in the glomerulus and was
mainly localized in the glomerular epithelial
cells. (B) Control animals showed faint staining
of VEGF in the glomerular epithelial cells. (C)
An increase in staining of eNOS was observed
in some of the glomerular capillary loops of
anti-GEN perfused rats. The staining was
localized to GEN. (D) No staining of eNOS
was observed in the control glomeruli
(Magnification x630).
is the concanavalin A (con A) model, which was originally
reported by Golbus and Wilson [29]. This is induced by perfusion
of a renal artery of rats with con A, a protein extract from the jack
bean Concanavalia ensefonnis, followed by antibody to con A. Con
A, which binds to the glomerular capillary wall [30], serves as a
planted antigen in the initiation of GEN injury. This model is
characterized by platelet and leukocyte infiltration [9, 31—34]. The
second model, which was developed by Matsuo's group, utilizes
another lectin, Lens culinaris hemoagglutinin, and anti-lectin anti-
body [35]. This model also results in GEN injury with platelet and
leukocyte infiltration. However, these models do not lead to
arteriolopathy and patchy cortical necrosis as observed in TMA.
Although our model is immunologically induced, which is not
believed to be the case in the classical post-diarrheal HUS due to
E. coli, our model demonstrated many features of renal microan-
giopathy. It should also be noted that HUS can also be secondary
to a variety of other disorders or be idiopathic, as described above.
Furthermore, although HUS is a typical disorder which shows
renal microangiopathy, various other disorders including SLE,
progressive systemic sclerosis, a primary antiphospholipid syn-
drome, and malignant hypertension demonstrate similar patho-
logical features of renal microangiopathy [4, 36—441. Renal
microangiopathy is known to be a high risk factor of progressing
to end-stage renal disease in SLE [451. Although the mechanism
of GEN injury in our model may be different from the classic
HUS, we believe that the GEN response to injury and many other
sequential events are similar, and that therefore this model will be
very useful to elucidate the pathologenic cascades which occur
following GEN injury in TMA and other renal microangiopathies.
A main feature of our model was acute renal failure, which was
clearly demonstrated by the histology and high BUN values in
uninephrectomized rats. The extremely high value of BUN in
uninephrectomized rats can be partly attributed to intravascular
hemolysis that accompanies this model. The lack of proteinuria in
the uninephrectomized rats may reflect the severe renal failure.
Histological analysis demonstrated characteristic features of renal
TMA. We also observed marked tubulointerstitial damage with
occasional regions of severe tubular necrosis, which is also seen in
severe HUS [46, 471. We did not detect any signs of histological
injury in other organs. This may be because we administered
anti-GEN antibody directly into the renal artery, and because of
relatively strong specificity of our antibody against GEN, although
we do not know exactly what antigens this polyclonal anti-GEN
antibody is directed toward.
A significant monocyte/macrophage infiltration was observed in
the glomerulus and in the interstitium. Various cytokines, such as
complement components and monocyte chemoattractant pro-
tein-i (MCP-1), can induce chemotaxis of macrophages. Cell
surface assembly of C5b-9 membrane attack complex induces
MCP-1 secretion from endothelial cells [48]. It was also demon-
strated that glomerular endothelial cells can produce MCP-1 in
vitro [49]. Considering the time course of macrophage accumula-
tion, it is possible that some cytokines such as MCP-i released by
GEN, rather than complement components, induced macrophage
infiltration in this model. Fibrin deposition and associated pro-
duction of fibrin degradation products can also facilitate attrac-
tion and activation of macrophages.
Although we observed mononuclear cells in capillary lumina at
10 minutes, the number of ED-i positive cells in glomeruli did not
show a statistically significant increase at that time point. How-
ever, the number of ED-i positive cells at 10 minutes (2.2 1.0
per glomerulus) was twice that of control rats (1.1 0.7), and we
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Fig. 11. Extracellular matrix protein. Accumulation of collagen type IV and laminin was observed in the glomeruli of anti-GEN perfused rats at day
I (collagen type IV, A; laminin, D) and day 3. Deposition of collagen type IV and laminin was demonstrated in the interstitium of anti-GEN perfused
rats at day 3 and day 10 (collagen type IV, B; laminin, E). Control rats showed no increase of collagen (C) or laminin (F) (magnification X400).
believe that the limited number of animals in each group may
have limited the ability to detect a statistical significance.
Interestingly, in contrast to previously reported GEN injury
models [9, 31—33, 50, 51], we did not observe neutrophil infiltra-
tion in the glomerulus.
GEN damage was suggested by decrease of staining with
anti-endothelial cell antibody REcA-1 at day I and day 3.
However, RECA-1 staining and glomerular morphology recov-
ered at day 10. This suggests that loss of GEN was followed by a
recovery with GEN proliferation. Consistent with this, we ob-
served significant cell proliferation at day 3. Double staining
suggested most of these proliferating cells were GEN.
Several growth factors, including VEGF, have been shown to
stimulate GEN proliferation in vitro [52, 53]. VEGF, also called
cells [54—56]. It was demonstrated that 25I-labeled VEGF binds
to the capillaries of glomeruli [57], and that glomerular endothe-
hal cells have receptors for VEGF [58]. Here we observed
upregulation of VEGF in glomerular epithehial cells at day 1.
VEGF was detected in podocytes, which was consistent with
previous findings [18, 59—62]. This localization makes interpreta-
tion of the role of up-regulated VEGF difficult given the flux of
the ultrafiltrate that will hamper the binding of podocytic VEGF
to the receptors on GEN on the other side of the GBM.
Interestingly, expression of n-smooth muscle actin was ob-
served in the glomerulus at day 3. The de novo expression of
n-smooth muscle actin is considered to be a marker of activation
of mesangial cells [63]. The mechanism of induction of n-smooth
muscle actin in this GEN injury model is unclear, but it may be a
vascular permeability factor (VPF), is a mitogen for endothelial result of "cross-talk" between mesangial cells and GEN. The
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Table 2. Immunochemical analyses
10 Minutes 4 Hours Day 1 Day 3 Day 10
GoatlgG ++ ++ --+ + +
Platelet ++ ++ ++ + - — —
Fibrin + ++ ++ ++ —
RECA-1 N N — dec dec N dec N
PCNA N (0.4 0.1) + (4.5 2.1) N (0.1 0.1)
Macrophage
glom N(2.2 1.0) N (1.1 0.4) N (1.2 0.3) + (3.5 0.9) N(1.0 0.1)
mt N N—+ ++ ++ ++
a-SM actin
glom — —---+ —
mt N + +
VEGF N ++ N N
eNOS + + N N
Collagen IV
glom ++ ++ N-+
mt + + ++
Laminin
glom ++ ++ N—+
mt + + ++
Abbreviations and symbols are: N, normal range; —, not detected; +, up-regulated; ++ markedly up-regulated; dec, decreased; glom, glomerular;
int, interstitial.
injured GEN may have induced phenotypic changes of the
mesangial cells by releasing cytokines [64]. The in vitro modula-
tions of mesangial cells by cytokines derived from endothelial cells
have already been reported [65, 66]. Matsuo's group also reported
proliferation of mesangial cells in their GEN injury model that
utilized an exogenous implanted antigen and they speculated that
the mechanism could be generation of growth factors by the
infiltrated cells [35].
a-Smooth muscle actin expression was also observed in the
interstitium. Induction of smooth muscle characteristics in the
interstitial cells of the kidney was thought to be due to the
"myofibroblast-like" phenotypic change of interstitial fibroblasts
[67, 68]. In addition, it was demonstrated that this alteration
parallelled the interstitial macrophage number, which suggested
that infiltrating macrophages elaborated some cytokines such as
TGF-f3 and exerted a paracrine effect on resident interstitial
fibroblasts to acquire a new phenotype [68]. It should be noted
that a-smooth muscle actin expression in the interstitium paral-
lelled the macrophage infiltration in our model as well. Similar
mechanisms may be working in our model.
We also examined the regulation of eNOS in this model,
because endothelium-derived relaxing factor/nitric oxide (NO) is
one of the major thromboregulatory systems in endothelial cells
[69, 70]. NO not only causes smooth muscle relaxation and
consequent vasodilation, but also inhibits platelet adhesion and
aggregation [71—76]. NO has been shown to play an important
role to prevent glomerular thrombosis in the pregnant state or
with endotoxin challenge [77—79]. Furthermore, clinical improve-
ment by administration of NO donor was reported in one case of
HELLP syndrome (hemolysis, raised liver enzymes, and low
platelets), one of a range of conditions characterized by throm-
botic microangiopathy that includes HUS [80]. eNOS was previ-
ously shown to be expressed in GEN [81, 82]. In the ATS models
of rats, a subtle increase of eNOS mRNA was detected by
ribonuclease protection assay [83]. Although we do not have data
on its enzymatic activity, our immunohistochemical data in this
study suggested up-regulation of eNOS in the glomerulus. We
speculate that eNOS was up-regulated in order to compensate for
platelet aggregation and ischemia. Up-regulation of constitutive
NOS in the kidney was also observed in norepinephrine-induced
acute renal failure rats [84]. Furthermore, elevation of plasma
concentrations of the NO metabolites, which was speculated to be
a result of eNOS induction, was reported in patients with HUS
[85].
In conclusion, we established a new rat model of renal micro-
vascular endothelial cells. This model showed severe acute renal
failure with marked platelet deposition in the glomerulus in
association with thrombocytopenia and anemia with fragmented
erythrocytes. Peritubular capillary endothelial cells were also
damaged, accompanied by severe tubular necrosis. Although the
glomerular change was very severe, one half of the glomeruli
recovered at day 10, while interstitial change leading to fibrosis
remained throughout our observation time course. Proliferation
of GEN was observed during the recovery stage. Up-regulation of
eNOS in the glomerulus, which we think is a compensatory
mechanism for the ischemia, was observed. We believe this model
will serve an important tool to investigate the pathophysiology of
renal microvascular diseases.
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